Jakarta Fever (Dengue) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Jakarta Fever (Dengue) – Panduan Medis Lengkap

Overview

Jakarta Fever is the local name often given to dengue fever in the capital city of Indonesia. Dengue is a viral infection transmitted by the bite of an infected Aedes mosquito (primarily Aedes aegypti and Aedes albopictus). The disease is endemic in tropical and subtropical regions, and Indonesia reports one of the highest numbers of cases worldwide.

Who it affects: All ages can be infected, but severe disease is more common in children, the elderly, and people with certain chronic conditions (e.g., diabetes, heart disease). Urban areas with dense populations and inadequate waste management—such as Jakarta—provide ideal breeding sites for the mosquito vectors.

Prevalence (2023 data):

  • Indonesia reported ≈ 150,000 confirmed dengue cases nationwide, with Jakarta contributing about 30 % of those cases.
  • Incidence peaks during the rainy season (November–April), when standing water proliferates.
  • According to the Ministry of Health, the case‑fatality rate for severe dengue has dropped to < 0.5 % thanks to improved clinical management, but thousands still die each year.

Symptoms

Dengue presents in three phases—febrile, critical, and recovery. Not every patient experiences all phases, and severity can range from mild to life‑threatening.

Febrile Phase (Days 1‑5)

  • High fever (39‑40 °C) that comes on suddenly.
  • Severe headache, especially behind the eyes (retro‑orbital pain).
  • Muscle and joint pain—the term “break‑bone fever” comes from this intense soreness.
  • Fatigue and weakness. Patients often feel exhausted even after the fever resolves.
  • Nausea, vomiting, and loss of appetite.
  • Skin rash (often maculopapular) that may appear 3‑4 days after fever onset.
  • Bleeding tendencies: mild nosebleeds, gum bleeding, or easy bruising.

Critical Phase (Days 3‑7)

  • Plasma leakage leading to sudden drop in blood pressure (warning sign of dengue shock syndrome).
  • Severe abdominal pain or persistent vomiting.
  • Bleeding becomes more pronounced: hematemesis, melena, or heavy menstrual bleeding.
  • Organ dysfunction such as elevated liver enzymes, renal impairment, or altered mental status.

Recovery Phase (Days 7‑10)

  • Gradual resolution of fever and pain.
  • “Reabsorption” of leaked fluid may cause a feeling of heaviness in the chest or shortness of breath.
  • Skin may develop a “petechial” rash that looks like tiny red spots.

Because symptoms overlap with other infections (e.g., malaria, chikungunya, COVID‑19), laboratory testing is essential for accurate diagnosis.

Causes and Risk Factors

What causes dengue?

Dengue is caused by four antigenically distinct serotypes of the dengue virus (DENV‑1 to DENV‑4), all members of the *Flaviviridae* family. Once a person is infected with one serotype, they develop lifelong immunity to that serotype but only temporary cross‑protection against the others. Subsequent infection with a different serotype increases the risk of severe disease due to antibody‑dependent enhancement (ADE).

Key risk factors

  • Geography: Living in or traveling to endemic areas (Jakarta, Surabaya, Semarang, etc.).
  • Urban environment: Crowded housing, inadequate waste disposal, and water storage practices that create mosquito breeding sites.
  • Seasonality: Rainy months amplify mosquito populations.
  • Age: Children < 15 years have higher rates of severe dengue.
  • Previous dengue infection: Secondary infection with a different serotype raises risk of hemorrhagic complications.
  • Underlying health conditions: Diabetes, hypertension, heart disease, chronic kidney disease, and immune suppression.
  • Gender: Some studies from Indonesia show a slight male predominance, possibly related to outdoor exposure.

Diagnosis

Early diagnosis guides proper fluid management and avoids unnecessary antibiotic use.

Clinical evaluation

  • History of recent travel to endemic area and exposure to mosquitoes.
  • Physical exam focusing on fever, rash, bleeding signs, and signs of plasma leakage (e.g., pleural effusion, ascites).

Laboratory tests

  • NS1 antigen detection (available 1‑7 days after symptom onset). Highly specific; rapid tests give results within 20 minutes.
  • Reverse transcription polymerase chain reaction (RT‑PCR): Detects viral RNA, most sensitive in the first 5 days.
  • IgM/IgG serology: IgM appears ~5‑7 days after infection; IgG rises later and indicates past exposure. Useful after day 5.
  • Complete blood count (CBC): Characteristic findings include leukopenia, thrombocytopenia (< 100 × 10⁹/L), and a rising hematocrit (sign of plasma leakage).
  • Liver function tests, serum creatinine, and electrolytes to monitor organ involvement.

Imaging (if needed)

  • Chest X‑ray or ultrasound to detect pleural effusion or ascites during the critical phase.

Treatment Options

There is no specific antiviral medication for dengue; treatment is supportive and focuses on maintaining fluid balance and monitoring for complications.

Fluid management

  • Oral rehydration (ORS) for mild cases with adequate intake.
  • Intravenous crystalloid solutions (e.g., isotonic saline or Ringer’s lactate) for patients with warning signs, persistent vomiting, or evidence of plasma leakage. Goal: restore intravascular volume without causing overload.

Medications

  • Acetaminophen (paracetamol) for fever and pain—max 4 g/24 h. Avoid NSAIDs (ibuprofen, aspirin) because they increase bleeding risk.
  • Antiemetics (e.g., ondansetron) for persistent nausea/vomiting.
  • Antibiotics are only indicated if there is a secondary bacterial infection.

Procedures

  • Platelet transfusion is reserved for severe bleeding or platelet count < 20 × 10⁹/L with active hemorrhage, per WHO guidelines.
  • Hemodynamic monitoring (continuous blood pressure, urine output) in severe cases.

Lifestyle & supportive measures

  • Bed rest and avoidance of strenuous activity during the febrile and critical phases.
  • Close monitoring of urine output (≥ 0.5 mL/kg/h) to gauge hydration.
  • Use of a digital thermometer to track temperature trends.

Living with Jakarta Fever (Dengue)

For patients recovering from dengue, the focus is on gradual return to normal activities and monitoring for late complications.

  • Hydration: Continue drinking water, oral rehydration solutions, and coconut water to replenish electrolytes.
  • Nutrition: Small, frequent meals rich in protein, vitamins (especially C and B‑complex), and easy‑to‑digest carbs.
  • Rest: Fatigue may persist for weeks; avoid heavy physical exertion until cleared by a clinician.
  • Follow‑up labs: Repeat CBC 48‑72 h after discharge to ensure platelet recovery and stable hematocrit.
  • Mental health: Experiencing a severe infection can be stressful; seek counseling if anxiety or depression develops.

Prevention

Because no specific cure exists, preventing mosquito bites is the cornerstone of dengue control.

Personal protection

  • Apply EPA‑registered repellents containing DEET (≥ 30 %), picaridin, or oil of lemon eucalyptus every 2‑3 hours.
  • Wear long‑sleeved shirts and pants, especially during dawn and dusk when *Aedes* mosquitoes are most active.
  • Use mosquito nets or screens on windows and doors.
  • Sleep under an insecticide‑treated bed net if air‑conditioning is unavailable.

Environmental control (community level)

  • Eliminate standing water: empty, clean, or cover containers (flower pots, barrels, old tires).
  • Use larvicides (e.g., temephos) in water storage tanks that cannot be emptied.
  • Participate in local “fogging” or “ultra‑low‑volume” spraying programs during outbreaks.
  • Promote proper waste management and drainage infrastructure.

Vaccination

The WHO‑approved tetravalent dengue vaccine (CYD‑TD; Dengvaxia) is indicated for individuals aged 9‑45 years who have had a documented prior dengue infection. In Indonesia, the vaccine is available only through a limited public‑health program; consult your physician about eligibility.

Complications

If dengue is not promptly recognized or managed, several serious complications can develop.

  • Dengue Hemorrhagic Fever (DHF): Marked by plasma leakage, severe thrombocytopenia, and spontaneous bleeding.
  • Dengue Shock Syndrome (DSS): Circulatory collapse due to massive plasma loss; can be fatal within hours.
  • Organ failure: Acute liver injury (transaminases > 1,000 U/L), acute kidney injury, myocarditis, or encephalitis.
  • Secondary bacterial infection from gut translocation, especially in patients with prolonged hospitalization.
  • Post‑dengue fatigue syndrome: Persistent malaise lasting months, reported in up to 20 % of severe cases.

When to Seek Emergency Care

Immediate medical attention is required if you experience any of the following warning signs, especially after the third day of illness:
  • Severe abdominal or chest pain lasting longer than 2 hours.
  • Persistent vomiting (more than three times in 24 h) or inability to keep fluids down.
  • Rapid drop in platelet count (< 20 × 10⁹/L) or sudden rise in hematocrit (> 20 % above baseline).
  • Bleeding from gums, nose, or under the skin (large bruises, petechiae) that does not stop.
  • Difficulty breathing, shortness of breath, or swelling of the legs.
  • Altered mental status—confusion, drowsiness, or seizures.
  • Signs of shock: cold, clammy skin; weak rapid pulse; low blood pressure; fainting.

Call emergency services (119 in Indonesia) or go to the nearest hospital with a qualified emergency department.

References

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References